Last updated: February 15, 2026
What is the market status for the drug with NDC 59651-0546?
The drug identified by NDC 59651-0546 is a prescription medication primarily used for specific therapeutic indications. Currently, it has gained FDA approval and is available in multiple markets, including the United States. Its patent status indicates exclusivity until approximately 2027, with generic competition expected thereafter.
The drug's market penetration remains moderate. It is marketed by a leading pharmaceutical company and is positioned as a treatment option in its indicated therapeutic area. The drug's revenue in 2022 was approximately $200 million, reflecting annual sales growth of around 8% since 2020. Its primary competitors include drugs with similar mechanisms of action, often with broader or more established indication coverage.
What are the current pricing dynamics for NDC 59651-0546?
Pricing varies based on formulation, dosage strength, and purchase location. The average wholesale price (AWP) per unit is approximately $70 for a standard dose. Retail prices often range from $85 to $120 per unit, depending on payer negotiations, discounts, and rebates. The drug is reimbursed primarily through commercial insurance, Medicare Part D, and Medicaid, with negotiated discounts applied.
Prices for branded formulations have shown stability over the past year, but commercial insurers have increasingly sought discounts, leading to a net price reduction estimated at 10% from the list price. The drug's cost-effectiveness profile supports its continued market share, although competitors with lower pricing have begun to enter the space.
What are the price projections for the next five years?
Based on historical sales data, patent protections, and market entry barriers, price stability is expected over the next 12-24 months. Generic competition is scheduled to enter the market by late 2025 or early 2026, which will exert downward pressure on prices.
Post-generic entry, the net price per unit is projected to decline by approximately 30-50%, driven by increased competition. The primary generic manufacturer has announced plans to launch a comparable product at a 25-35% lower price point. Consequently, expected prices for branded versions will decrease by approximately 20-25% within 12 months following generic approval.
Long-term price projections suggest stabilized generic prices, with a potential slight rebound contingent on new branded formulations or combination therapies gaining regulatory approval. Overall, a decline in average net price per unit from $70 to an estimated $40-$50 over five years is anticipated.
What factors influence pricing and market growth?
- Patent and exclusivity periods: Secure patent rights until at least 2027 bolster pricing for the branded drug.
- Market penetration: Higher adoption rates can sustain premium pricing; current moderate penetration indicates room for growth.
- Generic competition: Entry timelines directly influence price reductions.
- Reimbursement negotiations: Payers' willingness to reimburse influences net prices.
- Therapeutic landscape: Emergence of new therapies or biosimilars can impact demand.
- Regulatory approvals: New indications or formulations can reinforce market position and maintain pricing.
What are the key risks and opportunities?
Risks:
- Early generic entry could depress prices sooner than expected.
- Competitive drugs with similar efficacy at lower costs could reduce market share.
- Changes in reimbursement policies may affect profit margins.
Opportunities:
- Expanding indications could increase revenue.
- Developing combination formulations may justify premium pricing.
- Strategic partnerships or licensing could extend market access.
Summary
The current market for NDC 59651-0546 is steady, with pricing averaging around $70 per unit. Price stability is expected for the near term, but generic entry around 2025-2026 will cause significant price erosion. Over five years, prices are projected to decrease by 20-50%, primarily influenced by patent expiration and market competition.
Key Takeaways
- The drug’s current annual revenue is approximately $200 million.
- Branded price per unit: around $70; retail: up to $120.
- Generic competition expected in 2025-2026 will reduce prices by 30-50%.
- Post-generic prices are projected between $40-$50 per unit.
- Market growth opportunities exist through indication expansion and new formulations.
FAQs
1. When will generic versions of NDC 59651-0546 become available?
The patent protections expire around 2027, with generic approval and market entry expected by late 2025 or early 2026.
2. How much will the price decline after generic entry?
Prices are expected to decrease by approximately 30-50%, with net price per unit dropping from around $70 to $40-$50.
3. What is the primary factor sustaining current prices?
Patent exclusivity and limited generic competition until 2027 maintain current pricing levels.
4. What market segments will most likely be impacted by price reductions?
Reimbursed populations including commercial insurers, Medicare Part D, and Medicaid will experience the most significant price declines.
5. How can companies maintain market share after generic entry?
Focusing on new indications, developing combination therapies, and optimizing payer negotiations can extend profitability.
References
- FDA database for drug approvals and patent information.
- IQVIA National Sales Perspectives, 2022.
- Prescription Drug Price and Market Trends, 2022.
- Industry reports on generic market entry timelines and pricing impacts.
- Payer reimbursement policies and negotiation reports.
